Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Silverglade leaves CSPI

This article was originally published in The Tan Sheet

Executive Summary

After more than 25 years with the Center for Science in the Public Interest, Bruce Silverglade resigns as the advocacy group's director of legal affairs and joins the law firm Olsson Frank Weeda Terman Bode Matz as a principal Nov. 1. While at CSPI, Silverglade led the bipartisan campaign to enact the Nutrition Labeling and Education Act of 1990 and recently worked with FDA to identify and enforce against firms that make inappropriately aggressive nutrient and health claims that could make foods unapproved drugs (1"The Tan Sheet" March 8, 2010)

You may also be interested in...



FDA's Flurry Of Food Claim Warnings Sends Bold Enforcement Message

A spate of FDA warning letters detailing labeling violations and an open letter from Commissioner Margaret Hamburg largely quash any hopes the food industry might have had for regulatory latitude to make aggressive health claims

EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments

While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.

US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.

Topics

UsernamePublicRestriction

Register

PS017586

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel